TruAbutment Inc.
$204.0K 54 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
OCULUS, Inc.
OCULUS, Inc. reported $204,048.44 across General Payments, Research, and Ownership to 74 physicians and teaching hospitals across 74 transactions.
- $204.0K Below-median payer
- All-tracks total
- 74 Below-median volume
- Transactions
- 74 Below-median reach
- Recipients
- −$83.0K
- General Payments vs PY2023
OCULUS, Inc. reported $204,048.44 across all CMS Open Payments tracks (General + Research + Ownership) to 74 physicians and teaching hospitals in Program Year 2024 - ranking #994 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $204,048.44, averaging $2.8K per recipient.
OCULUS, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
28/100
Total payments
F
12/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer oculus-inc OCULUS, Inc.
$204.0K · #994/1,925 · 0.0% industry · PY2024
- TOT $204.0K
- RANK #994
- SHARE 0.0%
- TXN 74
- RCP 74
- CAT 6
- GEN $204.0K
- ΔGEN −$83.0K
- TOP1 26.7%
- PY 2024
Volume peers
Nearest volume peer: TruAbutment Inc. ($204.0K)
OCULUS, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
OCULUS, Inc.'s CMS-reported General Payments decreased by $83.0K (−28.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: OCULUS, INC.PY2023: OCULUS, INC.PY2024: OCULUS, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $287,062.22
- PY2024
- $204,048.44
What the Data Shows for OCULUS, Inc.
Three separate CMS disclosure tracks feed the all-tracks total above - General, Research, and Ownership/Investment - each reported under its own rules and combined here for one comparable figure. For OCULUS, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). CMS releases each Program Year roughly 12 months after it ends; the methodology page covers the full standardization basis.
Of the 6 general-payment categories charted below, "Honoraria" is the largest at $84.9K across 28 transactions, 41.6% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
OCULUS, Inc. made 6 types of general payments. "Honoraria" is the largest category at $84.9K, 41.6% of General Payments.
OCULUS, Inc. reports 6 general-payment categories - the top three are Honoraria (41.6%), Consulting Fee (24.5%), and Royalty or License (17.0%). The remaining 3 categories make up 16.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How OCULUS, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Honoraria | $84.9K | 28 | 41.6% |
| Consulting Fee | $50.0K | 16 | 24.5% |
| Royalty or License | $34.6K | 4 | 17.0% |
| Compensation for Services Other Than Consulting | $29.8K | 2 | 14.6% |
| Travel and Lodging | $3.3K | 8 | 1.6% |
| Food and Beverage | $1.4K | 16 | 0.7% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $159,400.00 (78.1%) of $204,048.44 in this company's General Payments records across 34 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for OCULUS, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Crystal M. Brimer O.D.
$54,400.00 across 5 reported transactions
- 2
Rolando Toyos M.D.
$41,500.00 across 5 reported transactions
- 3
Jack T. Holladay M.D.
$30,000.00 across 12 reported transactions
- 4
Marguerite B. McDonald M.D.
$20,000.00 across 4 reported transactions
- 5
Paul M. Karpecki O.D.
$13,500.00 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
OCULUS, Inc.'s spend rank (#994 of 1,925, bottom 48% by spend) and concentration rank (#853 of 1,838, top 46% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Intelivation Technologies, LLC : $30.3K total payments, HHI 1566
- Endotronix, Inc. : $38.2K total payments, HHI 1550
- Krystal Biotech Inc : $202.7K total payments, HHI 1544
- Lucid Diagnostics Inc. : $203.3K total payments, HHI 1539
- MIM Software Inc. : $67.1K total payments, HHI 1538
- Genesis Software Innovations, LLC : $10.8K total payments, HHI 1538
- OCULUS, Inc. (this company) : $204.0K total payments, HHI 1529
- Agios Pharmaceuticals, Inc. : $1.5M total payments, HHI 1523
- Stratus Medical, LLC : $83.5K total payments, HHI 1522
- TrackX Technology, Inc. : $44.2K total payments, HHI 1521
- Encore Medical, LP : $19.8M total payments, HHI 1521
- Kaneka Medical America LLC : $200.8K total payments, HHI 1518
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as OCULUS, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about OCULUS, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with OCULUS, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Siesta Medical, Inc.
$203.7K 13 recipients
Compare payment profiles
Austin Medical Ventures Inc
$204.6K 11 recipients
Compare payment profiles
ITF Therapeutics LLC
$205.4K 296 recipients
Compare payment profiles
Maquet Cardiopulmonary GmbH
$205.7K 14 recipients
Compare payment profiles
Vifor (International) Ltd.
$202.0K 30 recipients
Compare payment profiles
Put this to use
OCULUS, Inc. ranks #994 of 1,925 by all-tracks total payments, led by "Honoraria".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Honoraria" spend across every manufacturer, not just OCULUS, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.